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Abstract
Cell-based therapies have intriguing potential for the treatment of a variety of neurological disorders. One such example is
genetically engineered cytotoxic T lymphocytes (CTLs) that are being investigated in brain tumor clinical trials. The
development of methods for CTL delivery is critical to their use in the laboratory and clinical setting. In our study, we
determined whether CTLs can migrate through fibrin matrices and if their migration, survival, and function could be
modulated by adding chemokines to the matrix. Our results indicated that CTLs can freely migrate through fibrin matrices.
As expected, the addition of the monocyte chemotactic protein-1 (MCP-1), also known as chemokine C-C motif ligand 2
(CCL2), to the surrounding media increased egress of the CTLs out of the fibrin clot. Interleukin (IL) -2 and/or IL-15
embedded in the matrix enhanced T cell survival and further promoted T cell migration. The interleukin-13 receptor alpha 2
specific (IL-13R alpha2) T cells that traveled out of the fibrin clot retained the capacity to kill U251 glioma cells. In summary,
CTLs can survive and migrate robustly in fibrin matrices. These processes can be influenced by modification of matrix
constituents. We conclude that fibrin matrices may be suitable T cell carriers and can be used to facilitate understanding of
T cell interaction with the surrounding microenvironment.
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Introduction
Adoptive immunotherapy using genetically engineered cytotox-
ic T lymphocytes (CTLs) is being investigated as a potential
treatment for cancer in the central nervous system and elsewhere
[1,2]. Pilot clinical trials have been initiated to evaluate the
feasibility and safety of local-regional delivery of autologous IL13-
zetakine redirected CTL clones in patients with recurrent
glioblastoma (GBM). These results indicate the adoptive transfer
of tumor-specific cytotoxic T cells to the tumor bed is a promising
strategy, though its clinical application may be limited due to the
shortcomings of previous and current delivery methods.
While systemic delivery is appealing for its convenience, non-
specific targeting, high cell dosage requirements, and the presence
of the blood-brain barrier are formidable obstacles. In clinical
trials local delivery can be achieved using catheter-based delivery
systems. Catheter-based delivery systems, however, are associated
with risks such as infection and hemorrhage. Additionally,
catheter-based delivery systems used at our institution present
significant logistical challenges. First, injection results in the
formation of a pocket of T cells at the catheter tip because cell
sized particles cannot flow through the extracellular space. With
point source distribution, CTLs may have to seek and find distant
targets in the brain diminishing the chances of successful therapy.
Second, to attain an adequate dose, multiple injections are needed.
These multiple injections lengthen hospital stay creating more
cost, risk, and patient inconvenience. We hypothesized that T cells
could be delivered more efficiently by embedded them in a fibrin
matrix placed in the resection cavity during surgery. The fibrin
matrix is a commercially available (Baxter, Tisseel) biodegradable
adhesive obtained by a combination of human-derived fibrinogen
and thrombin, duplicating the last step of the coagulation cascade.
Tisseel is normally used in neurosurgery as a dural sealant and a
hemostatic agent. Studies have shown that the application of fibrin
glue to the brain is safe and well tolerated [3,4,5].
Our approach of using fibrin glue as a vehicle for CTLs has not
been previously described, though fibrin glue has been widely used
for delivery of a variety of cells [6,7,8,9,10,11,12,13,14,15]. Fibrin
matrices are employed not only as a cell carrier, but also as
suitable vectors for drugs and exogenous growth factors.
Therefore, there exists the potential to combine cell-based
therapies with modulating biological factors in the fibrin glue.
A prerequisite for use of fibrin matrices as a T cell delivery
vehicle is that the cells must be able to migrate out of the fibrin
clot. Additionally, these cells must survive the passage and remain
efficacious tumor killers. In this study, we demonstrated the ability
of T cells to robustly migrate through a bio-enhanced matrix while
maintaining potency against glioma cells.
Materials and Methods
Reagents
Recombinant human interleukin (IL) -2 was purchased from
Cell signaling. Recombinant human IL-15 and monocyte
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Systems (Minneapolis, MN). Each cytokine and chemokine was
reconstituted in PBS with 0.1% human serum albumin (PBS–
HSA) and stored at 220uC until time of use. On the day of
experimentation, aliquots were diluted in RPMI media to the final
concentrations as indicated.
Cell lines and Cultures
In our experiments, firefly luciferase (ffl+) expressing interleu-
kin-13 receptor alpha 2 specific (IL-13R alpha2) CTLs cells were
cultured in RPMI 1640 (Invitrogen) with 10% heat-inactivated
fetal calf serum (FCS), 25 mmol/L HEPES, and 2 mmol/L L-
glutamine supplemented with 50 U/mL rhIL-2 (Chiron). U251
glioblastoma cells were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% heat-inactivated FCS, 25 mmol/
L HEPES, and 2 mmol/L L-glutamine.
For conditioned medium, U251 cell lines were grown to 60–
90% confluency and cells were then transferred to serum-free
medium. 24 and 48 hours after the transfer, the cell-free
supernatants were collected.
Fibrin Matrix (Tisseel) Formulation and Dissolution
The sealer protein component (fibrinogen-containing compo-
nent) was reconstituted in aprotinin solution (Baxter Healthcare),
and the thrombin component was reconstituted in 30 mM CaCl2.
Both solutions were diluted to the appropriate concentration using
Trisbuffered saline (TBS) and 30 mM CaCl2 in TBS for the sealer
protein and thrombin components, respectively. Formulation 1
was composed of 2.5 mg/ml fibrinogen and 2.5 U/ml thrombin.
Formulation 2 was composed of 5 mg/ml fibrinogen and 5 U/ml
thrombin. Finally, Formulation 3 was composed of 5 mg/ml
fibrinogen and 1 U/ml thrombin. In select experiments tissue
plasminogen activator (tPA) was used to dissolve the fibrin clots to
determine the number of remaining T cells. The CellTiter-Glo
Luminescent Cell Viability Assay (Promega) was performed as a
surrogate for cell count.
Incorporation of T Cells in Fibrin Matrix and Chemotaxis
Assays
T cell/fibrin clot constructs were prepared in the following
manner. Following harvest with trypsin–EDTA, 100 ml of ffl+ IL-
13 zetakine CTLs (7.5*10
6 cells/mL) were mixed with 150 ml
sealer protein solution. 150 ml of thrombin solution was subse-
quently added to the sealer protein–cell solution and mixed by
tapping and tilting the plates. Then 400 ml of the combined
mixture was placed in 24-well 5 mm QCM Chemotaxis Cell
Migration Assay plates (Millipore). Plates were incubated in a 5%
CO2 incubator for 8, 24, or 48 hours. At each time point, the
number of T cells that migrated out of the clots from the upper
chamber to the lower chamber was assayed using the CellTiter-
Glo Luminescent Cell Viability kit and measured using a
luminescence plate reader. The number of T cells that had
migrated out of the fibrin matrix was calculated according to the
standard curve; then the percent migration was calculated by
dividing the number of collected T cells by number of initial T
cells placed in the clot and multiplying the result by 100.
Cytotoxicity of IL-13 zetakine CTLs passage through the fibrin
matrix may adversely affect the ability of CTLs to kill tumor cells.
The potency of the CTLs was assayed in the following manner.
Effector cells were used 13 to 15 days after stimulation with
muromonab-CD3 (OKT3) and irradiated feeder cells. 7.5610
5
IL-13 zetakine CTLs per fibrin clot were plated into the upper
chamber of 24 well chemotaxis assay plates. The CTLs that had
migrated out were collected after 24 hours. U251 ffl+ target cells
(200,000 cells/ml) were co-cultured with increasing numbers of
CD8+ effector zetakine CTLs in a 5% CO2 incubator. After 4 or
24 hours of incubation, Dual-Glo Luciferase Assay Reagent was
added to each well of the 96-well plate. The plate was incubated
for 10 minutes at room temperature, and luminescence was read
from 8 mm above the bottom of the plate on the luminescence
plate reader.
Human Chemokine Levels in Glioma-Conditioned
Medium
Chemokine levels of MCP-1, C-C motif ligand 5 (CCL5), and
C-X-C motif ligand 10 (CXCL10) were determined using their
respective Human ELISA Kits (Invitrogen) as per the manufac-
turers’ instructions. Briefly, samples, controls, MCP-1, CCL5 (data
not shown), or CXCL10 standards were incubated for 2 hours at
room temperature with a biotinylated Hu MCP-1, CCL5, or
CXCL10 Biotin Conjugate solution, and then incubated for
30 minutes at room temperature with Streptavidin-HRP Working
Solution. Absorbance detection of captured cytokines was
quantified by Optical Density using a Microplate Reader.
Stimulation of T Cells in the Fibrin Clots and Effect on
Survival and Migration
IL-2 and/or IL-15 were added to the fibrin matrix to investigate
whether T cell survival and migration could be enhanced. T cell–
fibrin clots were prepared as described above. IL-2 (500 u/ml), IL-
15 (100 ng/ml), or IL-2 + Il-15 were mixed into the fibrin clots.
The IL-2 and IL-15 concentrations were chosen based on previous
studies and our preliminary experiments [16]. The CellTiter-Glo
ATP assay was performed to quantify CTL migration after
24 hours.
Statistics
The means and standard deviations of the obtained data were
calculated. One-way analysis of variance (ANOVA) with post-hoc
testing was used for comparing means of three or more variables.
Statistical analysis was carried out using SAS software (SPSS
version 12.0.1) on a Microsoft Windows XP system. The threshold
for statistical significance was set at 0.05.
Results
T Cell Migration Through Low Viscosity Fibrin Matrices
It is essential that CTLs are able to travel through the fibrin clot
to reach their target. We examined the effect of viscosity on T cell
migration using 6 formulations of varying thrombin and
fibrinogen concentrations. T cells that had exited to the
surrounding media were collected and quantified using an ATP
assay as a surrogate of cell count. The CellTiter-Glo ATP assay
showed a highly linear relationship between cell count and
luminescence (R
2=.98; data not shown).
Formulation 1 of lower fibrinogen and thrombin concentrations
was not only less viscous but also allowed the most T cells (25%) to
move out of the fibrin glue (p,0.01) (Figure 1). Formulation 2
(5.0 mg/ml fibrinogen and 5.0 U/ml thrombin) and Formulation
3 (5.0 mg/ml and 1.0 U/ml) allowed only 5% of T cells to migrate
through the clot. T cells were not capable of passaging through the
fibrin matrix when concentrations of fibrinogen and thrombin
exceeded 5.0 mg/ml and 1.0 U/ml respectively (data not shown).
At concentrations lower than those reported in Formulations 1,
the fibrin glue did not form a clot, and therefore these formulations
were not further analyzed.
CTL Trafficking and Survival in a Fibrin Matrix
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e34652Figure 1. Effects of fibrin clot formulation and MCP-1 on T cell migration. (A) Microscopic evaluation (106) of T cell migration out of fibrin
matrix. 7.5610
5 T cells were mixed into a fibrin clot (Formulation 1). Substantial egress of T cells into surrounding media was visualized at 48 hours.
(B) Effects of formulation and MCP-1 on CTL migration. CTLs were added to Tisseel clots with varying concentrations of thrombin and fibrinogen
(Formulation 1–3). After 48 hours, ATP assays were performed to quantify the amount of CTLs able to migrate out of the clots and into the
surrounding media. The matrix with the lowest viscosity (Formulation 1) allowed for the most T cell migration (* p,0.01). In addition to viscosity,
effects of MCP-1 on migration were examined. For all formulations, the addition of MCP-1 to the surrounding media significantly increased T cell
migration out of the clot (# p,0.01). The data represents the means 6 SD of three independent experiments.
doi:10.1371/journal.pone.0034652.g001
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Migration Out of the Fibrin Clot
MCP-1 is a known T cell chemokine; its ability to penetrate into
fibrin matrices, however, was unknown. We indirectly examined if
MCP-1 could diffuse into the fibrin clot to promote CTL
trafficking. As shown in Figure 1, the addition of MCP-1 to the
media outside of the clot significantly increased CTL migration in
the three formulations shown (p,0.01).
In addition to secreting other CTL chemokines such as IL-8,
tumors can regulate activation of normal T cell expression and
secretion [17]. The collective effect of these chemokines on T cell
trafficking from the fibrin clot was assessed (Figure 2). CTLs in the
fibrin matrices were exposed to standard culture media or
conditioned media obtained from culturing U251 glioblastoma
cells. There was significantly (p,0.05) more migration out of the
clot when glioma-conditioned media was used.
The fate of T cells remaining in the clot was also assessed
because it was unclear if those cells were trapped or had perished.
The clots were dissolved with tPA, and the cells were quantified
using an ATP assay (Figure 2). Regardless of the type of media, the
total number of cells—CTLs in or out of the clot—was slightly
over 30% of the initial cell count. This indicated that one limiting
factor was T cell demise within the fibrin matrix.
Chemokine Level in Glioma-Conditioned Medium
We demonstrated that there was significantly more migration
out of the clot when glioma-conditioned media was used
compared to standard culture media. To further investigate the
mechanism for the observed trafficking of T cells in glioma-
conditioned media, we measured chemokine levels. MCP-1 and
CXCL10 were detected at high levels in glioma-conditioned
supernatants compared to standard culture media (p,0.01)
(Figure 3). Thus, the observed migrational response in Figure 2
may be a consequence of chemokine-dependent directional
migration.
IL-2 and IL-15 Alone or in Combination Enhances T Cell
Survival and Promotes Trafficking
Cell survival after implantation is a major concern. To enhance
survival and potentiate trafficking, the cytokines IL-2 and IL-15,
alone or in combination, were added to the fibrin matrix. Prior to
this experiment, we confirmed that IL-2 and IL-15 caused
expansion and an increase in the diameter of CTLs, the later
reflective of T cell health (data not shown). Addition of IL-2
(500 u/ml), IL-15 (100 ng/ml), or IL-2+Il-15 into the fibrin clot
dramatically (p,0.01) increased T cell egression at multiple time
points (Figure 4). In contrast, the CTL migration in the untreated
group decreased to almost 0% after 96 hours. The most trafficking
was seen when IL-2 and IL-15 were combined; 65% of CTLs had
migrated out. These findings suggest the proliferative effect of the
cytokines is preserved in the fibrin matrix.
IL-13R alpha2 CTLs That Migrate Out of the Matrix
Remain Potent Against U251 Glioma Cells
Whether CTLs are still potent after migrating out of the fibrin
clot is unknown. U251 glioma cells expressing firefly luciferase
(U251 ffl+) were co-cultured with increasing numbers of glioma-
specific primary IL-13 zetakine CTLs that had migrated out of the
fibrin matrix (Figure 5). Although U251 cells died in a time
dependent manner, glioma cell death was dose-dependent (in
terms of CTL to U251 ratio) only at a shorter treatment time
(4 hours). 24 hours after incubation U251 cells were almost
completely eradicated when cultured with a five fold greater
number of CTLs.
Discussion
Adoptive immunotherapy is a theoretically elegant approach for
the treatment of brain tumors; however, the optimal method to
deliver T cells has not been developed. We hypothesized that in
lieu of the catheter-based delivery system, T cells can be
distributed by using a fibrin matrix carrier that is placed into the
resection cavity at the time of surgery. This method would confer
potential advantages. One is that the viscous nature of the
substance improves localization of the T cells to the tumor bed,
preventing washout into the subarachnoid space. Another
potential advantage is that catheter implantation is not required
and therefore certain risks are avoided. The most important
potential benefits relate to dose and distribution. A much larger
dose can be delivered. Additionally, bioactive reagents can be
added to the fibrin matrix to enhance the survival and function of
the T cells.
Our finding that CTLs can passage through low viscosity fibrin
matrices is consistent with studies reporting migration through
Tisseel of fibroblasts, chondrocytes, neutrophils and monocytes
[18,19,20,21]. The concentration of fibrinogen and thrombin that
we determined as optimal (2.5 mg/ml fibrinogen and 2.5 U/ml
thrombin) is similar to those reported in Cox et al.’s study which
examined fibroblast migration through fibrin clots (5–17 mg/mL
fibrinogen and 1–167 U/mL thrombin).
Though it was obvious that high concentrations of fibrinogen
were inhibitory, the active or passive mechanism(s) responsible for
CTL egress out of Tisseel have not been defined. In vivo, tumor
cells secrete chemoattractants such as MCP-1 which play an
Figure 2. Effect of media on T cell migration and quantification
of viable T cells remaining in the fibrin matrix. CTLs were mixed
with Tisseel (Formulation 1) and cultured in either glioma-conditioned
media (GC-Media) or standard culture media (Media). Quantification of
cells performed 48 hours after incubation showed GC-Media to
significantly increase T cell migration out of the fibrin matrix (*
p,0.05). The combined total of cells remaining in and migrating
outside the clot (reported as a percentage of the initial cell number)
was approximately the same (,30%) regardless of the type of media
used. The data represents the means 6 SD of three independent
experiments.
doi:10.1371/journal.pone.0034652.g002
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recruiting CD4+ and CD8+ cells [22,23,24]. It was uncertain if
CTL chemotactic factors could diffuse from the surrounding
media into the clot to promote migration. We have found that
glioma cell line U251 produces sufficient levels of MCP-1 to
chemoattract T cell migration through fibrin clots in vitro. Our
data indicated that MCP-1 containing or glioma-conditioned
media—the later theoretically full of MCP-1 and other chemo-
kines—significantly enhanced T cell migration suggesting that
targeting of remote tumor cells is possible.
We allow that factors other than MCP-1 can enhance T cell
migration. Although no other study has examined CTL migration
using a fibrin clot, Nishimura et al. have shown that chemokines
such as CXCL10, also referred to as interferon gamma-induced
Figure 3. Cytokine concentrations in glioma-conditioned media (GC-Media) and standard culture media (Media). Cytokine
concentrations were measured using Human ELISA Kits. (A) Increased MCP-1 concentrations in GC-Media (* p,0.0001, 24 h or 48 h vs. control). (B)
Increased CXCL10 concentrations in GC-Media (* p,0.0001, 24 h or 48 h vs. control). The data represents the means 6 SD of three independent
experiments.
doi:10.1371/journal.pone.0034652.g003
Figure 4. Effects of IL-2 and IL-15 on CTL migration. IL-2 (500 u/
ml), IL-15 (100 ng/ml), or the combination of IL-2/IL-15 was added into
the fibrin clots (Formulation 1). ATP assays were performed to quantify
the number of T cells that had migrated out of the clots after 24, 48,
and 96 hours. T cell migration significantly increased out of treated
clots containing IL-2, IL-15, or both compared to untreated clots. The
data represents the means 6 SD of three independent experiments (*
p,0.01 IL-2, IL-15, or IL-2/IL-15 vs. untreated).
doi:10.1371/journal.pone.0034652.g004
Figure 5. Cytotoxicity of post-migration IL-13 zetakine CTLs.
Post-migration IL-13 zetakines were co-cultured with U251 glioma cells
at a ratio (CTL:U251) of 1:1 or 5:1. The viability of U251 cells was
determined using the Dual-Glo Luciferase Assay after 4 hours (A) and
24 hours (B) of incubation time. Increasing the co-culture ratio to 5:1
significantly decreased glioma cell survivability (* p,0.01). Regardless
of the co-culture ratio, glioma cells died in a time-dependent manner
(** p,0.001). The data represents the means 6 SD of three
independent experiments.
doi:10.1371/journal.pone.0034652.g005
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effector cells to the brain tumor site [25]. Our present study
showed that CXCL10, in fact, was present in high concentrations
in glioma-conditioned media and could potentially promote CTL
migration out of the fibrin clot. In addition to the identity of
chemokines, other variables such as the amount or type of
chemokine-secreting residual tumor may be important.
Even under optimal circumstances, without additional aid only
about one-fourth of the CTLs were able to leave the fibrin matrix.
We observed that most had perished by days 3–6. Survival varied
depending on the initial health of the T cells which corresponded
to their status in the stimulation cycle. Of the T cells remaining in
the matrix, over two thirds of the initial cells were no longer viable.
Improving viability would be expected to increase migration due
to an enlarged pool of available cells.
Adoptively transferred antigen-specific CTLs are highly depen-
dent on exogenous cytokines such as IL-2, IL-7, IL-15 and IL-21
for their continued growth and survival [26]. Systemic adminis-
tration of IL-2 has been used to enhance T cell expansion and
persistence in vivo [27]. Administration of lowdose IL-15 has been
shown to promote the persistence of adoptively transferred tumor-
specific T cells in murine tumor models; however, the systemic
toxicity and the expansion of unwanted cells, including regulatory
T cells, limit the clinical value of this strategy [28,29]. We
demonstrated that IL-2 and IL-15 added to the fibrin clot
improved survival, possibly caused proliferation, and subsequently
increased T cell migration by 2–3 fold.
Migration to the target is insufficient if the T cells lose their
capacity to kill the tumor cells during passage. IL-13 zetakine
CTLs have been previously shown to recognize and kill
glioblastomas and medulloblastomas expressing IL-13R alpha2
[30,31]. In fact, IL-13 zetakine CTLs have been shown to
recognize and eliminate brain tumor stem-like initiating cells [32].
Our data indicated that IL-13 zetakine CTLs that had moved out
of the fibrin matrix killed U251 glioma cells in a time and dose
dependent fashion. The optimal dose required in vivo has yet to be
determined. However, the observed dose dependency suggests that
larger doses possible with fibrin matrix delivery would confer a
significant advantage.
We have shown that robust migration can be achieved with IL-2
and IL-15, chemotaxis mechanisms are not impaired by the
matrix, and that CTLs that have passaged through the matrix
remain potent. The significant logistical and biological advantages
associated with this technique are promising but will need to be
confirmed in vivo and in future clinical trials.
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